sector medic suppli devic
 attract setup ahead control-iq launch
initi coverag buy
messag initi coverag buy rate pt
see remark med-tech turnaround stori manag success
guid compani go concern risk start market
cap year later yet revenu growth remain except
yoy share sinc march vs russel amid
investor concern sustain top line momentum see
attract entri point stock current valuat support long-
term growth outlook view upcom control-iq launch repres
tandem establish technolog leader insulin pump
market slim pump consist earn high mark patient small
discret form factor intuit user interfac meanwhil tandem devic updat
freed patient shackl pump could becom outdat earli
lifespan compani partnership also given user access
best-in-class cgm technolog made slim first sensor-aug pump
approv let patient make insulin dose decis without prick finger
first doubl check glucos level subsequ addit basal-iq
predict low glucos suspend featur given tandem custom ad layer
protect prevent hypoglycem event februari slim also becam first
devic approv fda ace program design could
give tandem potenti competit advantag adopt autom insulin deliveri
system increas shorten regulatori timelin futur pump approv
proprietari survey work suggest compani consumer-centr
approach earn strong follow diabet commun past
two year weve conduct seri survey target type diabet patient
respond recent survey see tandem rank pump
custom satisfact fourth consecut time least tie lead
custom loyalti rate fifth time row survey data also includ posit lead
indic tandem abil continu gain share go forward particular
current pump user indic would prefer switch tandem suggest
compani posit captur disproportion share patient
transit away old pump next quarter
expect upcom control-iq launch leapfrog tandem ahead mdt
control-iq first true hybrid close loop system capabl activ manag
high low glucos level without requir patient prick finger point
process ada june result nih-fund idcl studi demonstr
strong perform system control-iq outperform tradit sensor-
augment pump term time rang vs hyperglycemia vs
hypoglycemia vs tandem target launch control-iq
expect fda approv next-gen pump
convinc system abl live full potenti success
upgrad cgm sensor longer term tandem novel sport pump
launch intern expans ramp pump replac tailwind instal
base matur repres increment opportun continu top line momentum
model call tandem grow sale compound-annual-growth-rate outlook
believ support stock current valuat
initi buy rate price target valu share
forward ntm sale estim impli upsid potenti current level
page analyst certif import disclosur
tandem san diego ca base insulin pump manufactur accord mission
statement compani dedic improv live peopl diabet
relentless innov revolutionari custom servic customer-centr
approach first endear tandem patient physician alik compani
began sale slim pump system earn high mark small
discreet form factor intuit user interfac featur sleek touchscreen design
element set apart competit pump built older less eleg platform
next-gen slim launch tandem devic updat featur
enabl remot softwar updat allow user stay current latest
technolog advanc throughout life pump end
tandem leverag appeal product offer captur share
insulin pump market drive sale year
yet despit earli success concern tandem path profit capit need
impend launch hybrid close loop system weigh heavili
stock bottom novemb split-adjust
high four year earlier vs russel period tndm
turnaround began earnest three month later follow decis particip
secondari offer net tandem proce dexcom direct
invest show support key technolog partner provid
import valid tandem place within diabet devic ecosystem gave
compani breath room need re-establish momentum busi
time tandem solv cash crunch js decis exit insulin
pump market neg patient feedback combin creat
competit open compani tandem capit opportun june
fda approv basal-iq predict low glucos suspend algorithm made
slim second hybrid close loop system avail first offer
fingerstick-fre calibr thank compat market-lead
cgm sensor back slim basal-iq earli success oversea follow
close year nearli vs russel cap one
remark comeback stori histori medic devic sector
page analyst certif import disclosur
turnaround complet investor focu shift tandem abil
sustain top line momentum compani recent result left littl complain
opinion revenu increas yoy sale top
consensu past three quarter yet share cool
strong start year stock sinc march vs russel
ev/ntm sale multipl compress period
believ compani growth like moder go forward comp get
tougher see tandem well posit remain net share taker insulin
pump market year come driven strong exist product portfolio rich
pipelin control-iq sport ou expans model call tandem sale grow
compound-annual-growth-rate level believ support stock
current valuat result see attract entri point
figur revenu composit million
compani report guggenheim secur llc estim
research suggest tandem patient-friendli design earn strong
follow within diabet commun past two year weve conduct
seri survey target type diabet patient respond
recent edit patient tracker see includ insulin pump user
tandem pump slightli share estim
compani current hold insulin pump market patient basi
repres highest read survey date back
ask respond number question relat pump experi
includ overal satisfact level pump would choos
opportun switch today case tandem score top mark earn highest
custom satisfact score vs averag competitor
regist highest percentag current custom would opt stick
compani given chanc switch vs averag competitor ex-
 fourth consecut survey tandem rank custom
satisfact fifth compani least tie lead custom
loyalti rate survey data also includ posit lead indic tandem abil
continu gain share particular current pump user indic
would prefer switch tandem suggest compani posit captur
disproportion share patient transit away old pump
next quarter
page analyst certif import disclosur
beyond simpli bring consumer-ori mindset diabet space
tandem also push envelop insulin pump technolog tandem
devic updat freed patient shackl pump could becom outdat
earli lifespan compani partnership given user
access best-in-class continu glucos monitor technolog made slim
first sensor-aug pump approv let patient make insulin dose decis
without prick finger first doubl check glucos level
subsequ addit basal-iq predict low glucos suspend featur given
tandem custom ad layer protect prevent hypoglycem excurs
februari slim also becam first devic approv fda
altern control enabl infus ace pump program ace pump
equival icgm sensor design signifi devic meet specif
paramet special control set forth agenc includ accuraci reliabl
qualifi inclus compon interoper diabet manag
system beyond give tandem potenti advantag adopt autom insulin
deliveri system increas ace classif also enabl compani file
futur new product applic pathway shorten regulatori
timelin futur pump approv
page analyst certif import disclosur
basal-iq tandem first step path artifici pancrea algorithm
receiv fda approv june becam avail download slim
patient age older also use dexcom sensor predict low glucos
suspend plg featur design reduc frequenc durat
hypoglycem event lead fear complic diabet loss
conscious seizur even death softwar work analyz cgm trend
data predict glucos level minut suspend basal insulin
deliveri patient blood sugar expect drop mg/dl insulin deliveri
resum glucos level risen back safe level prolog studi
random patient either slim basal-iq sensor-aug
pump sap without plg algorithm basal-iq found reduc time
hypoglycemia increas hyperglycemia time rang
compar sap arm mean glucos level
treatment group importantli patient thought system
easi use said would use system frequent recent
tracker gaug initi patient feedback basal-iq among tandem pump
user sampl adopt nearli three quarter patient
describ upgrad improv call signific step
figur prolog time hypoglycemia
page analyst certif import disclosur
expect upcom launch control-iq leapfrog tandem ahead
medtron control-iq build basal-iq plg capabl autom
basal attenu featur instead suspend basal insulin deliveri altogeth
automat decreas insulin infus rate base hypoglycem risk result
smoother glucos read higher time rang control-iq also introduc
autom bolu dose reduc hyperglycemia key differenti vs medtron
combin two featur put tandem track first true
hybrid close loop system capabl activ manag high low glucos
read given integr dexcom sensor patient use control-iq
wont prick finger point process compar guardian
cgm medtron use requir least two daili calibr
recommend yet approv insulin dose without first confirm
read yet anoth fingerstick file pma non-adjunct
label juli
ada june result nih-fund intern diabet closed-loop
idcl studi demonstr strong perform control-iq system
trial random patient either tandem slim pump sensor
typezero incontrol close loop algorithm control-iq slim
alon group start time rang baselin sensor-
augment pump cohort maintain level cours trial
time rang close loop group improv mean glucos reduc
close loop arm time hyperglycemia
time hypoglycemia improv
impress system stay close loop mode time well
report time rang view somewhat underwhelm
investor initi reaction data clinician room quit
tandem expect launch control-iq end year softwar
upgrad avail free charg exist basal-iq user expect
commerci strategi result less immedi bolu new patient
new launch would normal entail abil upgrad later remov incent
patient think get new pump wait actual control-iq approv
nonetheless see control-iq launch import mileston tandem
page analyst certif import disclosur
longer term tandem believ next-gen sport pump could repres
anoth signific new growth opportun roughli half size slim sport
blur line patch pump tradit insulin pump system small
size allow either carri pocket worn on-bodi adhes sleev
infus set design allow patient disconnect desir
without wast insulin give freedom manag diseas
achiev compact form factor tandem away trademark touch display
fact sport wont display rather pump control primarili
via app user smart phone singl button remain devic
enabl patient administ insulin bolu event lose connect
phone interest featur includ wireless charg water resist
feet two hour vs feet min slim remot upgrad softwar
control-iq compat right gate thank ace pump design
expect sport signific appeal among current pumper
multipl daili inject patient manag note posit feedback focu
group mdi patient particular mani highlight system size
flexibl attract featur think form factor could make popular choic
pediatr patient well categori tradit enjoy edg
durabl pump manufactur one drawback sport smaller insulin
reservoir unit vs unit slim daili insulin
requir current slim user result tandem expect system
complementari slim rather complet replac exist platform
sport launch
beyond new product intern expans pump renew repres
import growth driver tandem go forward compani still earli
stage penetr intern insulin pump market estim
exit instal base share compar domest
page analyst certif import disclosur
even repres solid progress short period time sinc launch slim
ou tandem particularli good success partner
 js former distributor mani left without insulin pump bag
 js decis exit busi pump compani ship
intern manag indic vast major either
anima convers distributor stock compani guidanc call ou
sale rang believ could prove
conserv post first half year look ahead model
call tandem intern revenu grow compound-annual-growth-rate next four year
sale repres compani overal top line vs
outlook assum compani ou market share rise target
view achiev given strong product portfolio void left js exit
tandem instal base matur renew revenu also becom bigger
driver compani result durabl insulin pump reimburs
replac cycl tandem enter market mean first
custom becam elig new pump late compani record
renew pool upgrade-elig patient expand
estim renew volum track grow nearli pump
pump expect rapid growth trajectori flatten
tandem lap weaker new pump shipment number yoy
reacceler sharpli importantli figur
compani first intern custom begin becom upgrad elig toward
end forecast period
outsid custom base competit renew provid tandem
anoth opportun take share given rel recent entri market
compani custom make small percentag pump user
becom upgrad elig year date tandem new custom sale
come evenli mdi patient tri pump first time competit
convers recent tailwind js exit set fade next coupl
quarter last patient upgrad believ compani remain well
posit continu siphon patient time least
market leader address current weak poor sensor accuraci
page analyst certif import disclosur
estim world-wide insulin pump accessori market approach
revenu grow high-singl digit clip nearli peopl
use pump administ insulin global includ type diabet
leader space sinc acquisit minim hold
world-wide share posit today compani sell number pump
model current flagship product pair guardian cgm
sensor form hybrid close loop system first commerci avail
system incorpor predict low glucos suspend featur automat basal
titrat throughout day signific step toward eventu close loop artifici
pancrea platform elsewher insulet omnipod dispos patch pump
 market today uniqu design offer varieti advantag tradit
durabl insulin pump includ elimin tube connect pump
patient improv comfort increas conveni leverag
differenti featur set carv share posit particularli strong
figur estim insulin revenu market share geographi
compani report guggenheim secur llc estim
remain domin leader durabl pump segment tandem
succeed carv meaning share posit estim compani
current hold revenu share global includ oversea
ww share two year ago demonstr far compani
come short period time model call tandem ww revenu share rise
posit strong player behind
final roch last major competitor insulin pump market accu-check
combo system integr glucos meter accu-check aviva pump accu-
check spirit believ roch sizabl presenc europ roughli
share rel nich player prior decis exit domest
pump market end despit decis on-going weak core
bgm busi roch appear still interest innov diabet manag
technolog compani sign exclus distributor
senseon eversens implant cgm system select european countri
agreement sinc expand intern market howev continu
model roch net share loser
page analyst certif import disclosur
model ww insulin pump revenu grow driven
compound-annual-growth-rate underli patient instal base modest price pressur outlook
repres acceler market recent trajectori number patient
use insulin pump grow clip howev believ pickup
growth like given signific stride alreadi made
technolog wave new technolog expect come market next
year
note estim non-cov compani denot base public inform factset consensu data
compani report factset guggenheim secur llc estim
page analyst certif import disclosur
million instal anima market anima market growth medic suppli devic
diabet global epidem accord american diabet associ
american diabet popul preval
medicare-ag popul even higher rank seventh lead caus
death nationwid cite underli caus nearli case health
burden exert tremend financi toll total cost diagnos diabet
estim includ direct medic expens
lost product global estim adult diabet
nearli quadrupl sinc diseas contribut death year
diabet patient typic broken two main subgroup type diabet
suffer underli immun disord caus bodi cell target
beta cell pancrea produc insulin caus condit
unknown believ deriv combin genet environment factor
type patient usual diagnos children cdc estim
approxim patient cure type diabet patient
requir take lifelong regimen synthet insulin inject surviv
type diabet acquir metabol disord character increas insulin
resist although pancrea continu produc insulin total beta cell output may
also depress genet factor play role determin person suscept
type diabet usual caus obes lack exercis poor dietari habit
result treatment type diabet gener begin recommend lifestyl
chang unsuccess patient progress drug therapi eventu insulin-
intens treatment estim american suffer type
diabet approxim insulin depend
diabet number seriou health consequ without insulin bodi lose
abil regul blood sugar lead episod hyperglycemia high blood
glucos hypoglycemia low blood glucos hyperglycemia gener defin
blood glucos level mg/dl associ increas long-term risk
cardiovascular renal neurolog vision disord hypoglycemia mg/dl
acut issu brain requir continu suppli glucos function properli
earli symptom hypoglycem episod may includ dizzi confus rapid
heart rate treat lead seizur loss conscious even death
page analyst certif import disclosur
technolog effect manag diabet rapidli evolv insulin-depend
diabet must test blood sugar regularli throughout day tradit
done prick finger insert test strip drop blood self-
monitor blood glucos meter smbg read use determin insulin
dose patient usual inject multipl time day stay
within normal glucos rang challeng approach point-in-tim
blood glucos estim provid strip meter test provid inform
trend matter dilig patient use meter still obtain
small number read cours day
continu glucos monitor cgm address shortcom smbg cgm
system use transcutan sensor test glucos level interstiti fluid
skin sensor worn bodi attach transmitt relay blood
sugar read handheld receiv and/or smart phone new read taken everi
minut throughout day provid patient near real-tim visibl
glucos level trend facilit better manag diseas
figur show exampl patient test four time cours
day two elev read two within normal rang figur
read overlaid cgm data show patient actual spent
vast major day outsid normal rang
page analyst certif import disclosur
cgm sensor around two decad adopt began ramp
technolog reach import tip point receiv fda
approv first profession cgm system provid physician three
day worth download read establish baselin prescrib
therapi follow guardian sensor dexcom st
system first devic give patient access blood glucos trend
inform despit signific interest patient physician howev
technolog struggl gain traction initi sensor accuraci prove sub-optimal
payer balk foot bill expens new devic left patient still need
use tradit smbg meter daili calibr cgm sensor insulin
cours past decad improv sensor technolog mount
bodi evid demonstr superior cgm smbg mean
effect control glucos level turn tide estim
number patient use cgm devic rose compound-annual-growth-rate penetr
type segment rise period januari
approv dexcom first cgm system cover medicar
pace innov pick steam time sinc fda approv
dexcom cgm system eversens jun
bring new gener sensor market
abbott entri cgm space particularli impact dont
consid current version libr true cgm due inabl provid high/low
glucos alert abbott decis offer devic limit flash glucos
monitor capabl signific discount competit cgm product struck chord
patient payer allow expand instal base patient
less two year post launch give command share global cgm
market democrat cgm technolog coupl grow consensu within
clinic commun cgm standard care type diabet
also signific subset insulin-intens type popul rise
tide lift boat estim world-wide cgm sale rose
 revenu increas yoy model call global cgm
market top repres compound-annual-growth-rate period
figur world-wide cgm revenu forecast billion
compani report guggenheim secur llc estim
page analyst certif import disclosur
meanwhil insulin deliveri side long march toward artifici pancrea
also reach critic junctur insulin-depend diabet administ insulin
multipl daili inject mdi howev approach repres signific
burden patient term qualiti life may alway result accur dose
result research work year find better way
minim usher modern insulin pump market seri product launch
prior acquisit today estim
type insulin-intens type diabet util pump
provid predict precis insulin deliveri discret form factor
better fit patient live repres meaning advanc mdi
tradit pump still requir signific interact part patient input data
determin dose
artifici pancrea system seek close loop juvenil diabet
research foundat jdrf announc artifici pancrea project collabor
program bring togeth academ research compani goal
develop close loop artifici system regul blood sugar diabet
organ provid grant money ap research studi
ap system consist three main element cgm measur transmit real-
time glucos level softwar algorithm analyz inform translat
dose decis pump deliv insulin develop integr
compon requir web partnership allianc across diabet
devic technolog sector includ team watson
work googl verili unit
compani pump cgm technolog in-hous
insid track ap develop kick trial way back
test efficaci sensor-aug pump compar tradit insulin pump therapi
compani pump receiv fda approv septemb becom first
system avail incorpor predict low glucos suspend featur
automat basal titrat throughout day cross import
threshold jdrf ap develop pathway move organ
term second gener devic categori
page analyst certif import disclosur
time expect ap system becom treatment method choic
insulin-intens diabet beyond sensor pump technolog believ
softwar behind system play critic role determin success
advanc artifici intellig machin learn algorithm increasingli
leverag improv predict capac head hyper hypo event
happen person therapi base patient individu routin bodi
chemistri lead today number devic choic
categori set prolifer next year
autom insulin deliveri system promin featur ada meet june
main diabet player present updat respect program
convers around focus mostli product limit stanford
research report patient institut discontinu
use pump close loop set month respect believ
high attrit rate reflect complic natur system requir mani
interact keep pump auto mode problem medtron guardian
connect sensor patient studi cite sensor reason
stop given tandem reput consumer-focus engin cgm
partnership weak point area strength
control-iq launch result expect control-iq garner substanti interest
patient physician payer leapfrog tandem lead posit
within aid segment
long-term plan reclaim throne howev compani expect
approv next-gen pump design address mani
shortcom system design achiev time rang
time auto mode manag patient mean glucos level mg/dl
day night vs mg/dl control-iq also featur
algorithm automat handl miss meal announc capabl
deliv auto correct bolus per hour vs control-iq view
impress featur set still need gener clinic data back
aspir target
page analyst certif import disclosur
